Pharmacist Reviews Cut DRPs in CKD Patients on SGLT2s

📅 Jun 23, 2026 · Renal failure

Background Information

Pharmacist interventions reduce drug problems in CKD patients on SGLT2 inhibitors.

CKD patients often face medication burdens which can increase nephrotoxicity risks, impacting their health outcomes. In 72 patients, 69 drug-related problems were identified, with high acceptance (85.5%) of pharmacist recommendations. No overt nephrotoxic events were observed. This study highlights the importance of pharmacist-led reviews in managing polypharmacy and reducing nephrotoxic risks in CKD patients. However, further studies are needed for definitive conclusions. Pharmacist-led medication reviews reduce drug-related problems in CKD patients on SGLT2 inhibitors without observed nephrotoxic events.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Ozturk Yalcin Z, Erdut A, Haberal G, Arici M, Bayraktar-Ekincioglu A

Citation: Ozturk Yalcin Z, Erdut A, Haberal G, et al. Nephrotoxic medication burden and drug-related problems in patients with chronic kidney disease using SGLT2 inhibitors. Renal failure. 2026;48(1):2688512. doi:10.1080/0886022X.2026.2688512

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Full deep analysis for this article is still in progress. Check back soon.